Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

16/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI

Market Cap	32Cr 28Cr 26Cr 24Cr 46Cr 3.03TCr 47Cr 312.38Cr 120.87Cr 1.5TCr 120.75Cr 118.11Cr 5.2TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	42Cr 37Cr 34Cr 32Cr 59Cr 3.94TCr 60Cr 405.71Cr 156.99Cr 1.95TCr 156.83Cr 153.4Cr 6.75TCr	EV / Sales 2026 *	-	EV / Sales 2027 *	11.5x
Free-Float	95.04%	Yield 2026 *	-	Yield 2027 *	-

16/05	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/04	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
16/04	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/11	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
14/11	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
31/25/31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
27/25/27	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
24/25/24	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
27/25/27	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
18/25/18	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
15/25/15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
30/25/30	Northwest Biotherapeutics, Inc. announced that it expects to receive $2.85 million in funding from Yorkville Advisors Global LP	CI

16/05	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
30/04	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
21/04	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR
21/11	Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility	PR
15/11	Northwest Biotherapeutics: Q3 Earnings Snapshot	AQ

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	01/06/2007
Linda Powers CEO	Chief Executive Officer	71	08/06/2011
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	01/01/2000

Northwest Biotherapeutics, Inc Share Price OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	01/01/1998
Linda Powers CHM	Chairman	71	17/05/2007
Navid Malik BRD	Director/Board Member	57	01/04/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	-0.48%	-1.93%	+66.16%	+120.57%	5.56TCr
WUXI APPTEC CO., LTD.	+0.82%	+15.05%	+79.52%	+88.67%	5.22TCr
BIONTECH SE	+1.36%	+0.36%	-14.52%	-14.67%	2.31TCr
INSMED INCORPORATED	-1.04%	+7.91%	+3.91%	+413.05%	2.24TCr
WUXI BIOLOGICS (CAYMAN) INC.	+6.78%	+14.77%	+37.54%	-1.86%	1.73TCr
GENMAB A/S	+0.25%	+3.11%	+29.81%	-32.66%	1.59TCr
EXELIXIS, INC.	+2.89%	+5.51%	+25.42%	+188.41%	1.38TCr
PHARMAESSENTIA CORPORATION	-3.35%	+8.96%	+134.32%	+282.61%	1.35TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.21%	+11.01%	+33.13%	-	1.24TCr
Average	+1.27%	+4.78%	+43.92%	+130.51%	2.51TCr
Weighted average by Cap.	+0.85%	+5.13%	+49.87%	+122.06%

	2026 *	2027 *
Net sales	-	3.89Cr 3.41Cr 3.15Cr 2.95Cr 5.52Cr 367.27Cr 5.64Cr 38Cr 15Cr 181.52Cr 15Cr 14Cr 629.41Cr
Net income	-	-
Net Debt	9.61Cr 8.42Cr 7.77Cr 7.27Cr 14Cr 906.34Cr 14Cr 93Cr 36Cr 447.93Cr 36Cr 35Cr 1.55TCr	12Cr 11Cr 10Cr 9.45Cr 18Cr 1.18TCr 18Cr 121.36Cr 47Cr 582.47Cr 47Cr 46Cr 2.02TCr